Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002181Source: DataRank Database

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 0.713. It has been cited 115 times.

N/A

0.713DataRank · unranked

Scored on demand from live citation data

Open Access115 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (38 grants)Impact (FWCI 9.53)OA: goldTopics (83)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.713

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (24)

Edbert D Lu ORCID,O. Badillo ORCID,Shokoufeh Karimi ORCID,Eric V Liu,Whitney Tamaki ORCID

Live enrichment

PubMed:34083417 OpenAlex:https://openalex.org/W3165096196

National Institutes of Health

Grant: P30CA82103

National Institutes of Health

Grant: P30DK063720

National Institutes of Health

Grant: P50CA097257

National Institutes of Health

Grant: R01CA221969

National Institutes of Health

Grant: R33CA183692

National Institutes of Health

Grant: S101S10OD018040-01

National Institutes of Health

Grant: U01CA176287, R35NS105068, R01CA222965, K08CA201591

Cancer Research UK

Grant: A28592

Alex's Lemonade Stand Foundation for Childhood Cancer

Grant: YIA

Damon Runyon Cancer Research Foundation

Grant: DRG-2190-14

Swedish Research Council

Grant: 2018-05973

California Institute for Regenerative Medicine

Grant: CLIN2-10248

Prostate Cancer Foundation

Grant: Challenge Award

National Institutes of Health

Grant: 5U01CA217864-03

Integrating targeted and immunotherapy to treat genetically heterogeneous cancers

National Institutes of Health

Grant: 5R01CA194511-04

Immunotherapy of human bladder cancer

Swedish Research Council

Grant: unidentified

unidentified

National Institutes of Health

Grant: 3P30CA082103-21S2

Cancer Center Support Grant

National Institutes of Health

Grant: 1ZIACP000101-21

Human Studies of Diet and Nutrition

National Institutes of Health

Grant: 5R33CA183692-02

Integrating mass cytometric and transcriptomic profiles of solid tumors

National Institutes of Health

Grant: 5K08CA201591-03

Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells

National Institutes of Health

Grant: 5P50CA097257-12

BRAIN TUMOR SPORT GRANT

National Institutes of Health

Grant: 5P30DK063720-03

ISLET PRODUCTION FACILITY CORE

National Institutes of Health

Grant: 5R01CA223484-02

Determinants of prostate cancer sensitivity to PD-1 blockade

National Institutes of Health

Grant: 5R01CA222965-05

Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression

National Institutes of Health

Grant: 5R35NS105068-05

Preclinical development of breakthrough immunotherapy for brain tumors

National Institutes of Health

Grant: 5U01CA176287-03

Genetic network analysis of cancer targets

National Institutes of Health

Grant: 5R01CA221969-05

Improving the efficacy of mTOR inhibition

NCI NIH HHS

Grant: K08 CA201591

NCI NIH HHS

Grant: U01 CA176287

NCI NIH HHS

Grant: P30 CA082103

NCI NIH HHS

Grant: R01 CA244550

NCI NIH HHS

Grant: R01 CA194511

NCI NIH HHS

Grant: R01 CA223484

NIH HHS

Grant: S10 OD018040

NCI NIH HHS

Grant: R01 CA222965

NIGMS NIH HHS

Grant: T32 GM007618

NINDS NIH HHS

Grant: R35 NS105068

NCI NIH HHS

Grant: U01 CA217864

FWCI

9.53

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://jitc.bmj.com/content/jitc/9/6/e002181.full.pdf

publisherhttps://jitc.bmj.com/content/jitc/9/6/e002181.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2020-002181

journalhttps://doi.org/10.1136/jitc-2020-002181

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34083417

Fields of Study

Glioma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomics0301 basic medicine03 medical and health sciencesAnimalsBrain NeoplasmsCTLA-4 AntigenCell Line, TumorGlioblastomaHumansImmune Checkpoint InhibitorsMembrane ProteinsMiceProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryTumor EscapeXenograft Model Antitumor Assays

MeSH Terms

Immune Checkpoint InhibitorsAnimalsBrain NeoplasmsGlioblastomaHumansMembrane ProteinsTumor EscapeXenograft Model Antitumor AssaysCell Line, TumorT-Lymphocytes, RegulatoryMiceCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Keywords

GlioblastomaEvasion (ethics)Immune systemImmune checkpointRefractory (planetary science)Profiling (computer programming)Cancer researchMedicineImmunotherapyComputational biologyImmunologyBiologyComputer sciencetumorT-LymphocytesOncology and CarcinogenesisProgrammed Cell Death 1 Receptor610T-Lymphocytes, RegulatoryCell LineMiceRare DiseasesCell Line, Tumor6162.1 Biological and endogenous factorstumor microenvironmentAnimalsHumansCTLA-4 Antigendendritic cellsImmune Checkpoint InhibitorsRC254-282CancerCancer och onkologibrain neoplasmsBiomedical and Clinical SciencesNeurosciencesImmunology in the medical areabiomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensMembrane ProteinsBasic Tumor ImmunologyRegulatoryXenograft Model Antitumor AssaysBrain DisordersBrain CancerOrphan DrugGood Health and Well Being5.1 PharmaceuticalsCancer and OncologyImmunologi inom det medicinska områdetTumor Escape

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 8 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687633.v1figshare

Additional file 8 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687633figshare

Additional file 7 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687630figshare

Additional file 6 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687627.v1figshare

Additional file 7 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687630.v1figshare

Additional file 6 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687627figshare

Additional file 4 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687621figshare

Additional file 5 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687624figshare

Additional file 4 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687621.v1figshare

Additional file 5 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687624.v1figshare

Additional file 1 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687612.v1figshare

Additional file 2 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687615.v1figshare

Additional file 3 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687618figshare

Additional file 3 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687618.v1figshare

Additional file 2 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687615figshare

Additional file 1 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

10.6084/m9.figshare.26687612figshare